相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brain-derived neurotrophic factor reduces inflammation and hippocampal apoptosis in experimental Streptococcus pneumoniae meningitis
Danfeng Xu et al.
JOURNAL OF NEUROINFLAMMATION (2017)
Laquinimod treatment in the R6/2 mouse model
Gisa Ellrichmann et al.
SCIENTIFIC REPORTS (2017)
Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease
Giulia Cisbani et al.
BRAIN (2017)
PPAR-delta is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically
Audrey S. Dickey et al.
NATURE MEDICINE (2016)
Human-to-mouse prion-like propagation of mutant huntingtin protein
Iksoo Jeon et al.
ACTA NEUROPATHOLOGICA (2016)
Epigallocatechin gallate attenuates amyloid β-induced inflammation and neurotoxicity in EOC 13.31 microglia
James Cheng-Chung Wei et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease
Juan Carlos Corona et al.
FREE RADICAL BIOLOGY AND MEDICINE (2016)
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
Lucianne Dobson et al.
JOURNAL OF NEUROCHEMISTRY (2016)
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease
Jose Luis Lopez-Sendon Moreno et al.
JOURNAL OF NEUROLOGY (2016)
VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease
Javier Diaz-Alonso et al.
SCIENTIFIC REPORTS (2016)
Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders
Gemma Navarro et al.
FRONTIERS IN NEUROSCIENCE (2016)
Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?
Andrea L. J. Marschall et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2016)
Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
Marta Garcia-Miralles et al.
SCIENTIFIC REPORTS (2016)
Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease
Robert B. Laprairie et al.
MOLECULAR PHARMACOLOGY (2016)
Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection
Javier Egea et al.
BIOCHEMICAL PHARMACOLOGY (2015)
The role of tau in the pathological process and clinical expression of Huntington's disease
Romina Vuono et al.
BRAIN (2015)
The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway
C. Blazquez et al.
CELL DEATH AND DIFFERENTIATION (2015)
Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's disease
Arlene I. Ramsingh et al.
HUMAN MOLECULAR GENETICS (2015)
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients
Edward J. Wild et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Treating the whole body in Huntington's disease
Jeffrey B. Carroll et al.
LANCET NEUROLOGY (2015)
Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury
Pere Boadas-Vaello et al.
NEURAL REGENERATION RESEARCH (2015)
SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease
Ernest S. Smith et al.
NEUROBIOLOGY OF DISEASE (2015)
Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease
Amber L. Southwell et al.
NEUROBIOLOGY OF DISEASE (2015)
The choreography of neuroinflammation in Huntington's disease
Andrea Crotti et al.
TRENDS IN IMMUNOLOGY (2015)
The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios
Heike J. Wobst et al.
FEBS LETTERS (2015)
Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease
Maud Gratuze et al.
HUMAN MOLECULAR GENETICS (2015)
A systems-level misunderstanding: the plasma metabolome in Huntington's disease
Herminia D. Rosas et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation
Ulrike Traeger et al.
BRAIN (2014)
Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntingtons disease
Megha Maheshwari et al.
HUMAN MOLECULAR GENETICS (2014)
Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease
Han-Yun Hsiao et al.
HUMAN MOLECULAR GENETICS (2014)
Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain
Megan J. Dowie et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2014)
AAV-Dominant Negative Tumor Necrosis Factor (DN-TNF) Gene Transfer to the Striatum Does Not Rescue Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease
Laura Taylor Alto et al.
PLOS ONE (2014)
A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis
Francisco J. Carrillo-Salinas et al.
PLOS ONE (2014)
A Small Molecule TrkB Ligand Reduces Motor Impairment and Neuropathology in R6/2 and BACHD Mouse Models of Huntington's Disease
Danielle A. Simmons et al.
JOURNAL OF NEUROSCIENCE (2013)
Dose-dependent Neuroprotection of VEGF165 in Huntington's Disease Striatum
Stuart M. Ellison et al.
MOLECULAR THERAPY (2013)
Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease
Frank M. Longo et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Intrabodies as Neuroprotective Therapeutics
Anne Messer et al.
NEUROTHERAPEUTICS (2013)
Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington's Disease: Role of CB1 and CB2 Receptors
Sara Valdeolivas et al.
ACS CHEMICAL NEUROSCIENCE (2012)
Plant polyphenols attenuate hepatic injury after hemorrhage/resuscitation by inhibition of apoptosis, oxidative stress, and inflammation via NF-kappaB in rats
Borna Relja et al.
EUROPEAN JOURNAL OF NUTRITION (2012)
Mutant huntingtin impairs immune cell migration in Huntington disease
Wanda Kwan et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
Aitor G. Granja et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2012)
Bone Marrow Transplantation Confers Modest Benefits in Mouse Models of Huntington's Disease
Wanda Kwan et al.
JOURNAL OF NEUROSCIENCE (2012)
Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease
Jill Bouchard et al.
JOURNAL OF NEUROSCIENCE (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Impaired Heat Shock Response in Cells Expressing Full-Length Polyglutamine-Expanded Huntingtin
Sidhartha M. Chafekar et al.
PLOS ONE (2012)
Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis
Jan Thoene et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's Disease: A multimodal imaging study
Marios Politis et al.
HUMAN BRAIN MAPPING (2011)
Insight into the mechanism of laquinimod action
W. Brueck et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
The role of immunity in Huntington's disease
D. Soulet et al.
MOLECULAR PSYCHIATRY (2011)
Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments
David C. Butler et al.
PLOS ONE (2011)
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Stephen M. Massa et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Roles of Sema4D-Plexin-B1 Interactions in the Central Nervous System for Pathogenesis of Experimental Autoimmune Encephalomyelitis
Tatsusada Okuno et al.
JOURNAL OF IMMUNOLOGY (2010)
Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 Mice
Abigail Snyder-Keller et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2010)
A Futility Study of Minocycline in Huntington's Disease
Heidi Schwarz et al.
MOVEMENT DISORDERS (2010)
BEHAVIOURAL AND MOLECULAR CONSEQUENCES OF CHRONIC CANNABINOID TREATMENT IN HUNTINGTON'S DISEASE TRANSGENIC MICE
M. J. Dowie et al.
NEUROSCIENCE (2010)
Dual Beneficial Effects of (-)-Epigallocatechin-3-Gallate on Levodopa Methylation and Hippocampal Neurodegeneration: In Vitro and In Vivo Studies
Ki Sung Kang et al.
PLOS ONE (2010)
Cannabinoid CB2 Receptor Agonists Protect the Striatum Against Malonate Toxicity: Relevance for Huntington's Disease
Onintza Sagredo et al.
GLIA (2009)
Rrs1 Is Involved in Endoplasmic Reticulum Stress Response in Huntington Disease
Alisia Carnemolla et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease
Amber L. Southwell et al.
JOURNAL OF NEUROSCIENCE (2009)
Beyond the brain: widespread pathology in Huntington's disease
Jorien M. M. van der Burg et al.
LANCET NEUROLOGY (2009)
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
Maria Bjorkqvist et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Reduction in Cerebral Atrophy Associated with Ethyl-eicosapentaenoic Acid Treatment in Patients with Huntington's Disease
B. K. Puri et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2008)
Modulation of amyloid-β-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid
Aedin M. Minogue et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Microglial activation in presymptomatic Huntington's disease gene carriers
Yen F. Tai et al.
BRAIN (2007)
Mapping the human plasma proteome by SCX-LC-IMS-MS
Xiaoyun Liu et al.
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY (2007)
Ethyl-EPA in Huntington disease - Potentially relevant mechanism of action
Harald Murck et al.
BRAIN RESEARCH BULLETIN (2007)
Inhibitory effects of eicosapentaenoic acid on lipopolysaccharide-induced activation in BV2 microglia
Dong-Oh Moon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2007)
Differential expression of BDNF mRNA splice variants in mouse brain and immune cells
Niels Kruse et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates
Annette Dalrymple et al.
JOURNAL OF PROTEOME RESEARCH (2007)
Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis
Zhihao Xu et al.
NEUROCHEMICAL RESEARCH (2006)
Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models
Dagmar E. Ehrnhoefer et al.
HUMAN MOLECULAR GENETICS (2006)
Regional and cellular gene expression changes in human Huntington's disease brain
A Hodges et al.
HUMAN MOLECULAR GENETICS (2006)
Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice
EC Stack et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2006)
Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease
J. K. Ryu et al.
NEUROSCIENCE (2006)
Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease
JM Van Raamsdonk et al.
EXPERIMENTAL NEUROLOGY (2005)
Minocycline in phenotypic models of Huntington's disease
K Bantubungi et al.
NEUROBIOLOGY OF DISEASE (2005)
Eicosapentaenoic acid prevents LPS-induced TNF-α expression by preventing NF-κB activation
Y Zhao et al.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2004)
Effect of various catechins on the IL-12p40 production by murine peritoneal macrophages and a macrophage cell line, J774.1
D Ichikawa et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2004)
(-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury
R Li et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2004)
Minocycline in Huntington's disease: A pilot study
M Thomas et al.
MOVEMENT DISORDERS (2004)
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease
E Diguet et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease
JK Ryu et al.
EXPERIMENTAL NEUROLOGY (2004)
Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease
E Diguet et al.
ANNALS OF NEUROLOGY (2003)
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease
X Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes
C Zuccato et al.
NATURE GENETICS (2003)
Minocycline and doxycycline are not beneficial in a model of Huntington's disease
DL Smith et al.
ANNALS OF NEUROLOGY (2003)
DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype
TW Miller et al.
MOLECULAR THERAPY (2003)
Apoptosis in Huntington's disease
MA Hickey et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS
WH Zhang et al.
ANNALS OF NEUROLOGY (2003)
Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells
JK Kundu et al.
JOURNAL OF NUTRITION (2003)
Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice
E Fossale et al.
HUMAN MOLECULAR GENETICS (2002)
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
AV Panov et al.
NATURE NEUROSCIENCE (2002)
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice
S Zhu et al.
NATURE (2002)
The biochemistry of n-3 polyunsaturated fatty acids
DB Jump
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity
A Khoshnan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment
BK Puri et al.
NEUROREPORT (2002)
A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids
KS Vaddadi et al.
NEUROREPORT (2002)
Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease
JJ Clifford et al.
NEUROSCIENCE (2002)
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease
C Zuccato et al.
SCIENCE (2001)
Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease
JM Lecerf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice
DX Chen et al.
NATURE MEDICINE (2000)
Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor
MI Diamond et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
